ELAN
HealthcareElanco Animal Health Incorporated
$23.05
+$0.53 (+2.35%)
Jan 5, 2026
Price History (1Y)
Analysis
Elanco Animal Health Incorporated is a healthcare company operating within the drug manufacturers - specialty & generic industry. The firm has a significant scale, with a market capitalization of $11.45B and revenue of $4.59B in the trailing 12 months (TTM). Elanco also employs approximately 9,000 individuals. The company's financial health is characterized by moderate profitability, with gross margins at 55.0% and operating margins at 2.4%. Net income in the TTM was $36.00M, while EBITDA reached $882.00M. Elanco generated significant free cash flow of $504.12M, indicating a strong ability to produce cash from its operations. However, the company's balance sheet shows substantial debt at $4.32B, which is more than 64 times equity. Elanco's valuation metrics include a price-to-earnings ratio (TTM) of 329.29 and a forward P/E of 22.25. The revenue growth rate in the trailing year was 10.4%, while earnings growth is not reported.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Elanco Animal Health Incorporated
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Visit website →Key Statistics
- Market Cap
- $11.45B
- P/E Ratio
- 329.29
- 52-Week High
- $23.70
- 52-Week Low
- $8.02
- Avg Volume
- 5.40M
- Beta
- 1.87
Company Info
- Exchange
- NYQ
- Country
- United States
- Employees
- 9,000